{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T15:01:22Z","timestamp":1768662082051,"version":"3.49.0"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,15]]},"DOI":"10.2169\/internalmedicine.5596-25","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:07:50Z","timestamp":1750874870000},"page":"303-308","source":"Crossref","is-referenced-by-count":0,"title":["Drug-induced Lung Injury Caused by Azacitidine That Was Not Treated with Drugs"],"prefix":"10.2169","volume":"65","author":[{"given":"Hikaru","family":"Mamizu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Miyagatani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Mamizu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuru","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Niigata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hasserjian RP. Myelodysplastic syndrome updated. Pathobiology 86: 7-13, 2019.","DOI":"10.1159\/000489702"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 86: 306-314, 2007.","DOI":"10.1532\/IJH97.07034"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Onco 20: 2429-2440, 2002.","DOI":"10.1200\/JCO.2002.04.117"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Uchida T, Ogawa Y, Kobayashi Y, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 102: 1680-1686, 2011.","DOI":"10.1111\/j.1349-7006.2011.01993.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nguyen P, Safdar J, Mohamed A, et al. Azacitidine-induced pneumonitis and literature review. BMJ Case Rep 13: e236349, 2020.","DOI":"10.1136\/bcr-2020-236349"},{"key":"6","unstructured":"6. Camus PH, Foucher P, Bonniaud PH, et al. Drug induced infiltrative lung disease. In: Interstitial Lung Disease. 4th ed. Schwarz MI, King TE, Eds. BC Decker, Hamilton, 2003: 485-534."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Craig ED, Jeffey LM, James PU, Svetomir NM, Jay HR. Organizing pneumonia in patients with hemotologic malignancies: a steroid-responsive lesion. Respir Med 101: 162-168, 2007.","DOI":"10.1016\/j.rmed.2006.03.035"},{"key":"8","unstructured":"8. Yamakawa N, Mochizuki Y, Nakahara Y, et al. A case of myelodysplastic syndrome complicated with organizing pneumonia. Nihon Kokyuki Gakkaishi (Ann Jpn Respir Soc) 44: 933-937, 2006 (in Japanese)."},{"key":"9","unstructured":"9. Hosono T, Hironaka M, Bando M, et al. An autopsy case of myelodysplastic syndrome complicated by recurrent organizing pneumonia. Nihon Kokyuki Gakkaishi (Ann Jpn Respir Soc) 44: 185-191, 2006 (in Japanese)."},{"key":"10","unstructured":"10. Shimanuki Y, Suzuki T, Takahashi K, Fukuchi Y. A case of organizing pneumonia associated with myelodysplastic syndrome (MDS). Nihon Kokyuki Gakkaishi (Ann Jpn Respir Soc) 42: 665-670, 2004 (in Japanese)."},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Adams CD, Szumita PM, Baroletti SA, et al. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. Pharmacotherapy 25: 765-768, 2005.","DOI":"10.1592\/phco.25.5.765.63579"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Makita S, Munakata W, Watabe D, et al. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome. J Int Med Res 45: 886-893, 2017.","DOI":"10.1177\/0300060517698331"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nair GB, Charles M, Ogden L, et al. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome. Respir Care 57: 631-633, 2012.","DOI":"10.4187\/respcare.01338"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sekhri A, Palaniswamy C, Kurmayagari K, et al. Interstitial lung disease associated with azacitidine use. a case report. Am J Ther 19: e98-e100, 2012.","DOI":"10.1097\/MJT.0b013e3181e7a526"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Hueser CN, Patel AJ. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome. Pharmacotherapy 27: 1759-1762, 2007.","DOI":"10.1592\/phco.27.12.1759"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hayashi M, Takayasu H, Tada M, et al. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan. Intern Med 51: 2411-2415, 2012.","DOI":"10.2169\/internalmedicine.51.8167"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kuroda J, Shimura Y, Mizutani S, et al. Azacitidine-associated acute interstitial pneumonitis. Intern Med 53: 1165-1169, 2014.","DOI":"10.2169\/internalmedicine.53.1971"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ahrari A, Sabloff M, Bredeson C, et al. Rare respiratory and neurologic adverse reactions to azacitidine in the treatment of myelodysplastic syndrome of patients treated at the Ottawa hospital. J Hemotol 4: 231-234, 2015.","DOI":"10.14740\/jh227w"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Alnimer Y, Salah S, Abuqayas B, et al. Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature. J Med Case Rep 10: 15, 2016.","DOI":"10.1186\/s13256-016-0803-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Misra SC, Gabriel L, Nacoulma E, et al. How to diagnose early 5-azacytidine-induced pneumonitis: a case report. Drug Saf Case Rep 4: 4, 2017.","DOI":"10.1007\/s40800-017-0047-y"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oka S, Ono K, Nohgawa M. Delayed onset of azacitidine-associated pneumotitis: a case report. Am J Ther 26: e617-e620, 2019.","DOI":"10.1097\/MJT.0000000000000824"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Choi KH, Lee HB, Jeong MY, et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest 121: 1478-1485, 2002.","DOI":"10.1378\/chest.121.5.1478"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lappi-Blanco E, Soini Y, P\u00e4\u00e4kk\u00f6 P. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 177: 367-376, 1999.","DOI":"10.1007\/PL00007654"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Radzikowska E, Fijolek J. Update on cryptogenic organizing pneumonia. Front Med (Lausanne) 10: 1146782, 2023.","DOI":"10.3389\/fmed.2023.1146782"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Shimoda M, Tanaka Y, Morimoto K, et al. Spontaneous resolution of cryptogenic organizing pneumonia: observational study. Medicine (Baltimore) 102: e34277, 2023.","DOI":"10.1097\/MD.0000000000034277"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Choi KJ, Yoo EH, Kim KC, et al. Comparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia. BMC Pulm Med 21: 336, 2021.","DOI":"10.1186\/s12890-021-01707-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5596-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:34:06Z","timestamp":1768620846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5596-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5596-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"5596-25"}}